Nkarta, Inc. (NASDAQ:NKTX) Shares Bought by Barclays PLC

Barclays PLC grew its position in shares of Nkarta, Inc. (NASDAQ:NKTX) by 161.4% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 232,566 shares of the company’s stock after acquiring an additional 143,608 shares during the quarter. Barclays PLC owned about 0.33% of Nkarta worth $1,051,000 as of its most recent filing with the SEC.

Other institutional investors have also bought and sold shares of the company. Meeder Asset Management Inc. acquired a new stake in Nkarta in the 2nd quarter valued at about $26,000. GAMMA Investing LLC lifted its holdings in Nkarta by 110.9% in the 3rd quarter. GAMMA Investing LLC now owns 9,972 shares of the company’s stock valued at $45,000 after acquiring an additional 5,243 shares during the last quarter. Erste Asset Management GmbH acquired a new stake in Nkarta in the 3rd quarter valued at about $33,000. The Manufacturers Life Insurance Company lifted its holdings in Nkarta by 92.9% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 20,710 shares of the company’s stock valued at $122,000 after acquiring an additional 9,975 shares during the last quarter. Finally, Forefront Analytics LLC acquired a new stake in Nkarta in the 2nd quarter valued at about $70,000. Institutional investors and hedge funds own 80.54% of the company’s stock.

Wall Street Analysts Forecast Growth

NKTX has been the topic of several recent analyst reports. Needham & Company LLC cut their price objective on Nkarta from $13.00 to $11.00 and set a “buy” rating on the stock in a report on Friday, November 8th. RODMAN&RENSHAW upgraded Nkarta to a “strong-buy” rating in a report on Wednesday, October 9th. Rodman & Renshaw initiated coverage on Nkarta in a report on Wednesday, October 9th. They set a “buy” rating and a $14.00 price objective on the stock. Mizuho cut their price objective on Nkarta from $20.00 to $16.00 and set an “outperform” rating on the stock in a report on Thursday, November 21st. Finally, HC Wainwright cut their price objective on Nkarta from $22.00 to $18.00 and set a “buy” rating on the stock in a report on Monday, November 11th. Five research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $15.00.

Nkarta Price Performance

Shares of NKTX opened at $2.32 on Tuesday. The company has a market capitalization of $163.72 million, a price-to-earnings ratio of -1.23 and a beta of 0.82. Nkarta, Inc. has a fifty-two week low of $2.08 and a fifty-two week high of $16.24. The business’s 50-day moving average is $2.84 and its 200-day moving average is $4.51.

About Nkarta

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.